Dramatic changes in oncology care pathways during the COVID-19 pandemic: The French ONCOCARE-COV study.

Fiche publication


Date publication

octobre 2020

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr MERROUCHE Yacine, Dr DEBREUVE-THERESETTE Adeline


Tous les auteurs :
Brugel M, Carlier C, Essner C, Debreuve-Theresette A, Beck MF, Merrouche Y, Bouché O

Résumé

The coronavirus disease 2019 (COVID-19) pandemic may have affected cancer management. We aimed to evaluate changes in every oncology care pathway essential steps, from screening to treatment during the pandemic. Monthly oncological activity differences between 2019 and 2020 (screening tests, histopathological analyzes, multidisciplinary tumor board meetings (MTMB), diagnostic announcement procedures (DAP), and treatments) were calculated in two French areas experiencing different pandemic's intensity (Reims and Colmar). COVID-19 has had a dramatic impact in terms of screening (-86% to -100%), diagnosis (-39%) , and surgical treatment (-30%) . This global decrease in all essential oncology care pathway steps contrasted with the relative stability of chemotherapy (-9%) and radiotherapy use (-16%). Outbreak occurred earlier and with more intensity in Colmar but had a comparable impact in both areas regarding MTBM and DAP. The current ONCOCARE-COV study is still in progress, and with a longer follow-up to analyze post-lockdown situation.

Référence

Oncologist. 2020 Oct 28;: